Cubist Pharmaceuticals Inc (CBST) financial statements (2020 and earlier)

Company profile

Business Address 65 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2014
TTM
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 579976
Cash and cash equivalents 91104
Short-term investments 488872
Receivables 12393
Inventory, net of allowances, customer advances and progress billings 5842
Inventory 5842
Prepaid expense and other current assets31
Deferred tax assets 52 
Other undisclosed current assets 5814
Total current assets: 8701,157
Noncurrent Assets
Property, plant and equipment 178166
Long-term investments and receivables  3
Long-term investments  3
Intangible assets, net (including goodwill) 1,104267
Goodwill 383114
Intangible assets, net (excluding goodwill) 721153
Other noncurrent assets 98
Prepaid expense and other noncurrent assets66
Other undisclosed noncurrent assets 896273
Total noncurrent assets: 2,276775
TOTAL ASSETS: 3,1461,932
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 277209
Accounts payable 3246
Accrued liabilities 245164
Deferred revenue and credits 67
Other liabilities 74
Other undisclosed current liabilities 2039
Total current liabilities: 311259
Noncurrent Liabilities
Long-term debt and lease obligation 1,041466
Long-term debt, excluding current maturities 1,041466
Liabilities, other than long-term debt 437179
Deferred revenue and credits 3134
Deferred tax liabilities, net 358103
Liability for uncertainty in income taxes 1614
Other liabilities 3228
Other undisclosed noncurrent liabilities (37)38
Total noncurrent liabilities: 1,441683
Total liabilities: 1,752942
Stockholders' equity
Stockholders' equity attributable to parent 1,394991
Common stock 00
Additional paid in capital 1,362941
Accumulated other comprehensive income (loss) 0(0)
Retained earnings 3150
Total stockholders' equity: 1,394991
TOTAL LIABILITIES AND EQUITY: 3,1461,932

Income statement (P&L) ($ in millions)

9/30/2014
TTM
12/31/2013
12/31/2012
Revenues 1,054926
Cost of revenue
(Cost of Goods and Services Sold)
 (260)(230)
Gross profit: 794696
Operating expenses (847)(511)
Other undisclosed operating income 7952
Operating income: 26237
Nonoperating expense (70)(38)
Other nonoperating expense (35)(8)
Interest and debt expense (38)(33)
Other undisclosed income from continuing operations before equity method investments, income taxes 3833
Income (loss) from continuing operations before income taxes: (44)200
Income tax expense (benefit) 25(46)
Net income (loss) available to common stockholders, basic: (19)154
Other undisclosed net income available to common stockholders, diluted  17
Net income (loss) available to common stockholders, diluted: (19)171

Comprehensive Income ($ in millions)

9/30/2014
TTM
12/31/2013
12/31/2012
Net income (loss): (19)154
Comprehensive income (loss): (19)154
Other undisclosed comprehensive income, net of tax, attributable to parent 00
Comprehensive income (loss), net of tax, attributable to parent: (18)154

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: